Catheter ablation vs. anti-arrhythmic drug therapy for ventricular tachycardia in ischaemic heart disease: a meta-analysis of randomized controlled trials
Authors:
- Francesco SantoroFrancesco Santoro
- Giacomo MugnaiGiacomo Mugnai
- Laura PerrottaLPLaura Perrotta
- Boldizsar KovacsBKBoldizsar Kovacs
- Leon DinshawLDLeon Dinshaw
- Alvaro Marco del CastilloACAlvaro Marco del Castillo
- Christiane JungenCJChristiane Jungen
- Stefan Kurath-KollerSKStefan Kurath-Koller
- Stefan StojkovićSSStefan Stojković
- Bert VandenberkBVBert Vandenberk
- Kevin VernooyKVKevin Vernooy
Open Access
- 29 November 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Abstract
Aims: Ventricular tachycardia (VT) in ischaemic heart disease (IHD) requires complex management strategies including catheter ablation (CA) and anti-arrhythmic drugs (AADs). The aim of this study is to compare efficacy and safety of CA vs. AADs in patients with IHD and VT. Methods and results: We performed a meta-analysis of randomized controlled trials (RCTs) enrolling patients with IHD and ICD randomized to CA or AADs. Primary outcome was appropriate ICD therapy. Secondary outcomes included inappropriate ICD therapy, cardiovascular (CV) re-hospitalization, all-cause/CV mortality, and adverse events. Subgroup analyses were conducted for amiodarone and sotalol, with an exploratory evaluation of a composite endpoint (ICD shock, VT storm, all-cause death). Four RCTs including 947 patients (mean age 68 ± 2 years; 93% male) were analysed. CA significantly reduced the risk of appropriate ICD therapy compared with AADs (149/470 [31.7%] vs. 229/477 [48.0%]; RR 0.81; 95% CI [0.67, 0.97]; P = 0.02). Among secondary outcomes, CA decreased the incidence of CV re-hospitalization [RR 0.84; 95% CI (0.72, 0.99); P = 0.04] and adverse events [RR 0.42; 95% CI (0.28, 0.62); P < 0.01], while no differences were observed in all-cause/CV mortality and inappropriate ICD therapy. In subgroup analyses, CA was superior to sotalol in reducing the composite endpoint of ICD shock, VT storm and all-cause death [RR: 0.82, 95% CI (0.69, 0.98), P = 0.03]; whereas, no significant benefit was seen compared to amiodarone [RR: 0.92; 95% CI (0.78, 1.09), P = 0.32]. Conclusion: In ischaemic heart disease and VT, CA compared with anti-arrhythmic drugs is associated with a reduction of appropriate ICD therapy, cardiovascular re-hospitalization, and adverse events with benefits most evident versus sotalol.Keywords
This publication has 42 references indexed in Scilit:
- Catheter ablation vs advanced therapy for patients with severe heart failure and ventricular electrical stormHeart Rhythm, 2024
- Preprocedural imaging with cardiac computed tomography for endo-epicardial ventricular tachycardia ablationHeart Rhythm, 2024
- 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summaryHeart Rhythm, 2018
- Durability of wide-area left atrial appendage isolation: Results from extensive catheter ablation for treatment of persistent atrial fibrillationHeart Rhythm, 2017
- Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group studyHeart Rhythm, 2015
- Prevalence of Regional Myocardial Thinning and Relationship With Myocardial Scarring in Patients With Coronary Artery DiseaseJAMA, 2013
- Comparison of β-Blockers, Amiodarone Plus β-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter DefibrillatorsThe OPTIC Study: A Randomized TrialJAMA, 2006
- Clinical safety profile of sotalol in patients with arrhythmiasThe American Journal of Cardiology, 1990
- Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarctionThe American Journal of Cardiology, 1986
- Side effects and complications of amiodarone therapyAmerican Heart Journal, 1985